News Headlines Article

Pfizer to buy Array BioPharma in deal worth $11.4 billion
USA Today

Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion.

Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline of targeted cancer medicines in development and a portfolio of other medicines that are expected to generate significant royalties over time.

It announced significant advancement in the treatment of colorectal cancer last month.